452 related articles for article (PubMed ID: 9546217)
1. Capture of an early fusion-active conformation of HIV-1 gp41.
Furuta RA; Wild CT; Weng Y; Weiss CD
Nat Struct Biol; 1998 Apr; 5(4):276-9. PubMed ID: 9546217
[TBL] [Abstract][Full Text] [Related]
2. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
Ferrer M; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Wiley DC; Harrison SC
Nat Struct Biol; 1999 Oct; 6(10):953-60. PubMed ID: 10504731
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
[TBL] [Abstract][Full Text] [Related]
4. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage.
Kliger Y; Gallo SA; Peisajovich SG; Munoz-Barroso I; Avkin S; Blumenthal R; Shai Y
J Biol Chem; 2001 Jan; 276(2):1391-7. PubMed ID: 11027678
[TBL] [Abstract][Full Text] [Related]
5. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process.
Bär S; Alizon M
J Virol; 2004 Jan; 78(2):811-20. PubMed ID: 14694113
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
Keller PW; Morrison O; Vassell R; Weiss CD
J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
[TBL] [Abstract][Full Text] [Related]
7. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion.
Dimitrov AS; Rawat SS; Jiang S; Blumenthal R
Biochemistry; 2003 Dec; 42(48):14150-8. PubMed ID: 14640682
[TBL] [Abstract][Full Text] [Related]
8. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
[TBL] [Abstract][Full Text] [Related]
9. A synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusion.
Pritsker M; Jones P; Blumenthal R; Shai Y
Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7287-92. PubMed ID: 9636141
[TBL] [Abstract][Full Text] [Related]
10. Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity.
Louis JM; Bewley CA; Clore GM
J Biol Chem; 2001 Aug; 276(31):29485-9. PubMed ID: 11418583
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.
Kliger Y; Shai Y
J Mol Biol; 2000 Jan; 295(2):163-8. PubMed ID: 10623516
[TBL] [Abstract][Full Text] [Related]
12. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
Liu S; Lu H; Niu J; Xu Y; Wu S; Jiang S
J Biol Chem; 2005 Mar; 280(12):11259-73. PubMed ID: 15640162
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
Derdeyn CA; Decker JM; Sfakianos JN; Wu X; O'Brien WA; Ratner L; Kappes JC; Shaw GM; Hunter E
J Virol; 2000 Sep; 74(18):8358-67. PubMed ID: 10954535
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41.
Weng Y; Weiss CD
J Virol; 1998 Dec; 72(12):9676-82. PubMed ID: 9811701
[TBL] [Abstract][Full Text] [Related]
15. Interhelical interactions in the gp41 core: implications for activation of HIV-1 membrane fusion.
Wang S; York J; Shu W; Stoller MO; Nunberg JH; Lu M
Biochemistry; 2002 Jun; 41(23):7283-92. PubMed ID: 12044159
[TBL] [Abstract][Full Text] [Related]
16. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
Jiang S; Debnath AK
Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike.
Eggink D; de Taeye SW; Bontjer I; Klasse PJ; Langedijk JPM; Berkhout B; Sanders RW
J Virol; 2016 Dec; 90(23):10587-10599. PubMed ID: 27654295
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.
Lawless MK; Barney S; Guthrie KI; Bucy TB; Petteway SR; Merutka G
Biochemistry; 1996 Oct; 35(42):13697-708. PubMed ID: 8885850
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
20. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
Eckert DM; Kim PS
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11187-92. PubMed ID: 11572974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
